QuintilesIMS maakt prijs van preferente obligaties bekend
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Quintiles IMS Holdings, Inc. heeft vandaag de prijs bekendgemaakt van zijn uitgifte van preferente obligaties ter waarde van 1,425 miljard euro, die worden verkocht door zijn dochteronderneming Quintiles IMS Incorporated. Dit is een opschaling van de eerder aangekondigde obligatie-uitgifte met een totale waarde van 850 miljoen euro. Als gevolg van deze uitbreiding kiest Quintiles ervoor niet langer zijn term-B-kredietfaciliteit te verruimen. Het bedrijf is nog wel voornemens alle uitstaande term-B-leningen van zijn preferente en gedekte kredietfaciliteit te herfinancieren met een verlengde en opnieuw geprijsde term-B-faciliteit, zoals eerder is aangekondigd. De netto-opbrengst van de obligatie-uitgifte en de herfinanciering worden gebruikt voor de financiering van bestaande schulden, betaling van kosten die verbonden zijn met de obligatie-uitgifte en andere bedrijfsactiviteiten, die mogelijk bestaan uit het terugkopen van aandelen van dochterondernemingen en belangrijke aandeelhouders en overnames.
QuintilesIMS Announces Pricing of Senior Notes |
|||||
|
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Quintiles IMS Holdings, Inc. (“QuintilesIMS”) (NYSE: Q) today announced the pricing of the offering of €1.425 billion in gross proceeds of senior notes to be issued by its wholly owned subsidiary, Quintiles IMS Incorporated (the “Issuer”). The offering was upsized from the previously announced €850 million aggregate principal amount. As a result of the upsize, while the Issuer still intends to refinance all of the outstanding term B loans under its senior secured credit facility with an extended and repriced term B loan facility as previously announced, it has elected to no longer upsize the term B loan facility. The net proceeds from the notes offering, together with proceeds from the previously announced proposed refinancing, will be used to refinance certain of the Issuer’s existing indebtedness, to pay fees and expenses related to the notes offering and the refinancing and for other general corporate purposes, which may include share repurchases, including the repurchase of shares from affiliates and significant shareholders, and future acquisitions. The notes will bear interest at a rate of 3.25% and will pay interest semi-annually in arrears on March 15 th and September 15 th of each year beginning on September 15, 2017. The notes will mature on March 15, 2025. The issuance of the senior notes is expected to occur on or about February 28, 2017, subject to customary closing conditions. Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors including the failure to consummate the notes offering and the refinancing and potential changes in market conditions that could cause actual results to differ materially. This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes. The notes have not been, and will not be, registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933. The notes are being offered only to qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act of 1933 and outside the United States only to non-U.S. investors pursuant to Regulation S. About QuintilesIMS QuintilesIMS (NYSE: Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles Transnational and IMS Health, QuintilesIMS’s approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes through treatment innovations, care provision and access can leverage QuintilesIMS’s broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial, bringing customers a unique opportunity to realize the full potential of innovations and advanced healthcare outcomes. As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, and to identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes. QUINTILESIMSFIN Click here to subscribe to Mobile Alerts for QuintilesIMS. View source version on businesswire.com: http://www.businesswire.com/news/home/20170223006817/en/ Contacts Quintiles IMS Holdings, Inc. |
|||||